Among the 50 identified driver genes (Fig. 2a; Supplementary Table 4), tumors harboring EGFR driver mutations exhibited a significantly longer tumor latency than those without EGFR driver mutations, with a median of approximately 6.3 more years from the time of subclonal diversification in comparison to tumors with no EGFR driver mutations (FDR=8.25e-05). The gene discussed is EGFR; the disease is neoplasm.